Arrowhead Pharmaceuticals disclosed early clinical signals from RNAi programs targeting adipose biology that, when paired with Lilly’s tirzepatide (Zepbound), produced larger fat and weight reductions than tirzepatide alone. The company is advancing these candidates toward Phase 2, highlighting compelling reductions in visceral and liver fat in initial cohorts. Arrowhead framed the data as proof‑of‑concept for targeted adipose delivery of gene‑silencing therapeutics in metabolic disease.